LUND, Sweden, Sept. 25, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced that a date for a follow- up meeting with the U.S. Food and Drug Administration (FDA) has now been confirmed. The meeting will...
from PR Newswire: https://ift.tt/2lA0VvM
No comments:
Post a Comment